This is a contrast between VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Gamida Cell Ltd. (NASDAQ:GMDA) based on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides us the return on equity, net margins and return on assets of both companies.

Liquidity

The Current Ratio of VistaGen Therapeutics Inc. is 4.9 while its Quick Ratio stands at 4.9. The Current Ratio of rival Gamida Cell Ltd. is 6.5 and its Quick Ratio is has 6.5. Gamida Cell Ltd. is better equipped to clear short and long-term obligations than VistaGen Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for VistaGen Therapeutics Inc. and Gamida Cell Ltd.

VistaGen Therapeutics Inc. has a 1,975.47% upside potential and a consensus price target of $22. Meanwhile, Gamida Cell Ltd.s consensus price target is $16, while its potential upside is 261.17%. The data provided earlier shows that VistaGen Therapeutics Inc. appears more favorable than Gamida Cell Ltd., based on analyst view.

Insider & Institutional Ownership

Roughly 20.4% of VistaGen Therapeutics Inc. shares are owned by institutional investors while 13.1% of Gamida Cell Ltd. are owned by institutional investors. Insiders owned 0.2% of VistaGen Therapeutics Inc. shares. Comparatively, 65.61% are Gamida Cell Ltd.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year VistaGen Therapeutics Inc. was more bearish than Gamida Cell Ltd.

Summary

On 6 of the 11 factors VistaGen Therapeutics Inc. beats Gamida Cell Ltd.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, which is in Phase 1 clinical trials for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original post:
Reviewing VistaGen Therapeutics Inc. (VTGN)'s and Gamida Cell Ltd. (NASDAQ:GMDA)'s results - MS Wkly